The German Thorotrast study: Recent results and assessment risks

Citation
G. Van Kaick et al., The German Thorotrast study: Recent results and assessment risks, RADIAT RES, 152(6), 1999, pp. S64-S71
Citations number
23
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Experimental Biology
Journal title
RADIATION RESEARCH
ISSN journal
0033-7587 → ACNP
Volume
152
Issue
6
Year of publication
1999
Supplement
S
Pages
S64 - S71
Database
ISI
SICI code
0033-7587(199912)152:6<S64:TGTSRR>2.0.ZU;2-N
Abstract
The German Thorotrast study comprises 2,326 patients and 1,890 controls. Fo rty-eight Thorotrast patients and 239 controls are still alive and are invi ted far a follow-up examination every 2 years. In the deceased patients, th e following neoplastic diseases with excess rates were registered (Thorotra st/controls): liver cancer (454/3); cancer of the bile ducts, including gal lbladder (42/7); myeloid leukemia (40/7); myelodysplastic syndrome (30/4); plasmacytoma (10/2); nonHodgkin's lymphoma (15/5); bone sarcoma (4/1); mali gnant peritoneal or pleural mesothelioma (9/0). Dose calculations are based on results of whole-body counting, X-ray films, and data obtained from the hospital records on the volume of Thorotrast injected. For liver canter, t he cumulative risk estimate was calculated to be 40 per 10(4) person Sv (ra diation weighting factor = 20). These figures are close to the results of t he Danish study and are comparable to the results of the Life Span Study of A-bomb survivors after 40 years at risk with 18 to 48 liver cancers per 10 (4) person Sv. For hematopoietic malignancies, the cumulative risk was calc ulated to be about 7 per 10(4) person Sv (radiation weighting factor = 20). This risk estimate is lower by a factor of 10 compared to the results of t he Life Span Study. (C) 1999 by Radiation Research Society.